How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Journal of Thrombosis and Haemostasis · 2026-06 · 24 (6) · 2040-2042
DOI: 10.1016/j.jtha.2026.03.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-06. Verfasst von Michael Makris. Beteiligte Einrichtung: School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Electronic address: m.makris@sheffield.ac.uk. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Electronic address: m.makris@sheffield.ac.uk.
Zitieren
APA
Makris, M. (2026). How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?. Journal of Thrombosis and Haemostasis, 24(6), 2040-2042. https://doi.org/10.1016/j.jtha.2026.03.012
Vancouver
Makris M. How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?. Journal of Thrombosis and Haemostasis. 2026;24(6):2040-2042. doi:10.1016/j.jtha.2026.03.012
BibTeX
@article{Makris2026,
author = {Makris, Michael},
title = {How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {6},
pages = {2040--2042},
doi = {10.1016/j.jtha.2026.03.012}
}
EUVIMED